Healthcare
MiMedx Group, Inc.(MDXG)
Live Price
Offline$3.71
+0.27% today
1Y Change
-37.92%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $550.00M
- Revenue Growth
- +20.0%
- EPS Growth
- +13.8%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MiMedx Group, Inc. (MDXG) is a Healthcare stock with a market cap of $550.00M and listed on NASDAQ. The stock last traded around $3.71 and down 37.9% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +20.0%, EPS growth of +13.8%, a dividend yield of 0.0%. What stands out right now is revenue +20.0%, EPS +13.8%, free cash flow +13.1% with operating margin 10.2% and ROIC 10.8%. Valuation is more restrained than many high-expectation growth names at P/E 17.8 and price/sales 1.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MDXG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.0% vs +7.6% peer median
Operating Margin
Below sector median
+10.2% vs +19.4% peer median
P/E
Below sector median
17.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +20.0% and EPS at +13.8%, with operating margin around 10.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +8.7% | +18.4% | +18.8% |
2026 Feb 25, 2026 | +55.6% | -6.4% | -8.7% | -22.3% |
2025 Oct 29, 2025 | +114.3% | +2.9% | +10.7% | -4.3% |
Benchmark Edge
MDXG vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MDXG
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MDXG Max Drawdown
-61.18%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MDXG and SPY.
Company Overview
MiMedx Group, Inc.
NASDAQ Capital Market
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
- Leadership
- Joseph H. Capper
- IPO Date
- Feb 12, 2008
- Employees
- 837
- Street Address
- 1775 West Oak Commons Court, NE
- Mailing
- Marietta, GA, 30062
- Region
- Marietta, GA, US
- Reporting Currency
- USD
- Investor Line
- 770 651 9100
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 17.8
- EV/EBITDA
- 7.0
- Price/Sales
- 1.4
- Price/Book
- 2.2
Growth
- Revenue
- +20.0%
- EPS
- +13.8%
- Free Cash Flow
- +13.1%
Profitability
- Gross Margin
- 81.0%
- Operating Margin
- 10.2%
- Net Margin
- 7.9%
- ROE
- 12.9%
- ROIC
- 10.8%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 5.39
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.